PHARMACEUTICAL PREPARATIONS FOR ADDICTION TREATMENT

用于成瘾治疗的药物制剂

• 批准号: 2664208
• 负责人: RAM B. MURTY
• 金额: $ 16.89万
• 依托单位: MURTY PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2664208
• 关键词: drug /agent; drug abuse chemotherapy; drug administration routes; drug design /synthesis /production; drug detection; drug metabolism; drug quality /standard; drug screening /evaluation; pharmacology; toxicology

The Contractor shall serve as a drug formulations resource in support of preclinical pharmacological/ toxicological evaluations and clinical trials. In brief, the objectives of this contract are to determine the physical and chemical characteristics of a drug substance into clinically useful formulations. It involves identifying the chemical characteristics of the drug and its compatibility with various solvents, reagents and inactive ingredients, and its stability to environmental conditions (e.g., light, temperature, humidity). The formulation must be compatible with the route of administration intended, the drug's metabolism upon administration and its ability to achieve a clinically effective tissue/target concentration. Patient compliance issues, such as: ease of use; frequency and route of administration; and diversion to illegal use must also be considered with formulating a new dosage or a new drug substance. The data and products generated by this contract will be utilized by the NIDA Medications Development Division (MDD) in developing and testing pharmaceutical preparations in the treatment of drug addictions.

承包商应作为药物制剂资源提供支持